. Military Space News .




.
EPIDEMICS
Medical breakthroughs set to buoy AIDS council of war
by Staff Writers
Paris (AFP) July 15, 2011

The biggest medical forum on AIDS kicks off on Sunday to a buzz of excitement about potential strategies for curbing a pandemic that has now claimed 30 million lives in its three-decade history.

A four-day conference in Rome will mull dramatic evidence that drugs designed to treat patients with HIV can be used to shield uninfected people from the AIDS virus.

This could be the best news in 15 years, when antiretroviral drugs started to transform the human immunodeficiency virus (HIV) from a death sentence to a manageable disease.

It opens up dazzling options for rolling back a pandemic for which there is still no cure or vaccine, say some experts.

"Over the past 18 months, there has a been a string of good results from trials, and this has generated a fair bit of optimism," Jean-Francois Delfraissy, director of the French Agency for AIDS Research (ANRS), told AFP.

"Until recently, no one had found a medical way to prevent HIV -- all there was, essentially, was the condom and the message of safe sex."

The conference will gather thousands of specialists, ranging from virologists to pharmacologists and disease trackers.

It is staged once every two years by the International AIDS Society (IAS), which also organises the International AIDS Conference, a bigger event that touches on the pandemic's many social dimensions.

Here are the main causes for all the excitement:

-- a trial conducted among "sero-discordant" heterosexual couples in Africa, meaning couples in which one partner had been tested positive HIV while the other was uninfected.

The risk of HIV infection fell by a whopping 96 percent when the infected partner started early use of daily antiretrovirals.

-- a trial conducted among sero-discordant heterosexual couples in Kenya and Uganda which took a quite different tack. It asked the uninfected partner to take the daily anti-HIV pill.

The risk of infection fell 62 to 73 percent compared with couples where the uninfected partner took a placebo.

"This is a major scientific breakthrough which reconfirms the essential role that antiretroviral medicine has to play in the AIDS response," Michel Sidibe, executive director of UNAIDS, said on Wednesday.

"These studies could help us to reach the tipping point in the HIV epidemic."

Some campaigners say "treatment as prevention" -- treating infected people swiftly so that they do not infect others -- should now spearhead the war on AIDS.

In 2009, more than 33 million people were living with HIV and 2.6 million people became newly infected, according to UNAIDS.

"If you start early treatment for people infected with HIV, you get a 96.3-percent decrease in transmission," Julio Montaner, director of the BC Centre for Excellence in HIV/AIDS in British Columbia, Canada, said in a phone interview.

"Nothing else has been shown that is as efficacious. And the cost benefit is triple, because it decreases morbidity, it decreases mortality and it decreases transmissions. I call it a hat-trick, you can't have it any better."

Now, though, comes the devil of detail, which will fully occupy the Rome conference.

Will the results from a trial -- where volunteers are enthusiastic and encouraged by their partner to follow their pill regimen -- be equally valid when extended to the messiness of real life?

And what about the risk that people become over-confident and forgo use of a condom?

Giving HIV pills to uninfected, as opposed to infected, people raises even more issues.

Antiretrovirals can cause toxic side effects and carry a potentially hefty cost if they have to be taken daily for prevention. The price has fallen to as little as 25 US cents per tablet, but this is still a big discouragement for people who are living on a couple of dollars a day or less.

IAS chief Bertrand Audoin said the prevention trials, combined with proof that male circumcision helps protect men from HIV, showed "we are in the middle of huge scientific breakthroughs that could change the course of the epidemic in coming years."

He cautioned, though: "One of the challenges we have to meet is to align the scientific evidence with policies implemented on the ground."




Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola

.
Get Our Free Newsletters Via Email
...
Buy Advertising Editorial Enquiries


New drug adds to arsenal against AIDS
Paris (AFP) July 15, 2011 - A new drug, rilpivirine, can add powerfully to the combination of medications used to control HIV for first-time patients, researchers conclude in Friday's issue of The Lancet.

Rilpivirine, marketed by pharmaceutical firm Tibotec under the brand name of Edurant, is both safe and effective and its side effects are fewer and less severe compared with the widely-used efavirenz, or Sustiva, they say.

Combination therapy for new HIV patients commonly entails giving either efavirenz or nevirapine in conjunction with drugs of a separate class in order to attack the human immunodeficiency virus (HIV) from different angles.

Efavirenz and nevirapine are equally effective at suppressing HIV but can cause severe side effects, which is why there has been a search for a substitute drug in their class.

The two studies report on data from two trials carried out among nearly 1,400 patients in 21 countries.

Rilpivirine, a so-called second generation antiretroviral, was approved for combination therapy in May by the US Food and Drug Administration (FDA).

The study appears in the runup to a four-day medical conference, starting in Rome on Sunday, on the state of the HIV/AIDS pandemic.

Acquired immune deficiency syndrome (AIDS) has claimed some 30 million lives since the first recorded cases emerged in June 1981. At least 33 million people are living with HIV, according to UN estimates for 2009.





. Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.

Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle



EPIDEMICS
AIDS: HIV drugs boost prevention hopes
Paris July 13, 2011
Heterosexuals who take daily AIDS drugs reduce the risk of being infected by the human immunodeficiency virus (HIV) by nearly two-thirds, ground-breaking studies said on Wednesday. Campaigners hailed what they described as a powerful new weapon in the three-decade war against AIDS. "This is a major scientific breakthrough which reconfirms the essential role that antiretroviral medicine h ... read more


EPIDEMICS
New Missile Warning Satellite Delivers First Infrared Imagery

STSS Demonstration Satellites Demo New Remote Cueing Capabilities During Aegis Test

Israel to join U.S. Mideast missile shield

Raytheon gets $1.7 billion Patriot deal

EPIDEMICS
Iran says fired missiles into Indian Ocean

Northrop Grumman-Led ICBM Prime Integration Team Participates in Test Launch of Minuteman III Missile

Taiwan testfires own sub-launched missile: report

Raytheon UK Awarded Four-Year Support Contract for U.K. Paveway

EPIDEMICS
Unmanned Global Hawk Completes First Production Acceptance Multi-Intelligence Sensor Flight

Northrop Grumman to Help US Navy Study Options for Developing Fleet of Carrier-Launched Unmanned Systems

X-47B Can Operate From an Aircraft Carrier

Flapping micro air vehicles inspired by swifts

EPIDEMICS
Raytheon BBN Technologies Awarded $2.4 Million to Advance Satellite Communications

Raytheon Wins Competitive Long Term Evolution Broadband Communications Network Contract

Battlefield Airborne Communications Node System Completes 2,000 Tactical Missions

Track24 Defence releases SCC Titan

EPIDEMICS
Boeing: Boeing EA-18G Growlers Complete 1st Combat Deployment

12 dead in blasts at Cyprus base, navy chief killed

F-35 Jet Blast Deflector Testing Underway at Lakehurst

Lockheed Martin Achieves Significant Information Technology Services Milestone

EPIDEMICS
Brazilian jet fighter deal more distant

Germany's controversial Saudi tank deal

Bolivia forces assemble 6 Chinese warplanes

Merkel defends silence on reported Saudi tank deal

EPIDEMICS
Obama decides to meet Dalai Lama, upsetting China

Hopeful Dalai Lama welcomes young monk to US

Top US, Chinese officers hold talks

EU defence ambitions stuck in no-man's land

EPIDEMICS
System Integration of High Energy Laser Technology Demonstrator Completed

Raytheon Acquires Directed Energy Capabilities of Ktech Corporation


Memory Foam Mattress Review
Newsletters :: SpaceDaily Express :: SpaceWar Express :: TerraDaily Express :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News
.

The content herein, unless otherwise known to be public domain, are Copyright 1995-2011 - Space Media Network. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement